AtG Therapeutics (Barcelona) is a biotech company pioneering first-in-class therapies to outsmart resistant cancer. Built on 15+ years of research at ICO and IDIBELL, our TACTIC platform has identified TA-1, a novel target driving tumor adaptation. By inhibiting TA-1, our potent oral small molecules exploit adaptive synthetic lethality to selectively eliminate resistant cancer cells.
Gabriela Alejandra Jiménez: Co-Founder & COO // Gabriela@atgtx.com
Orio Casanovas: Co-Founder & interim CEO
Bart Huisken: Co-Founder & Business and Financial Strategist
AtG Therapeutics has developed a novel oncology platform to outsmart resistant cancer by targeting tumor adaptation—one of the key mechanisms driving treatment failure. Our approach centers on inhibiting Tumor Adaptation Factor 1 (TA-1), an enzyme overexpressed in aggressive, therapy-resistant tumors. AtG is advancing a portfolio of potent, orally available small molecules that selectively inhibit TA-1, disrupting cancer’s ability to survive under therapeutic stress.
This strategy exploits adaptive synthetic lethality: while TA-1 inhibition is harmless to normal cells, it becomes lethal to cancer cells that rely on tumor reprogramming for survival. Designed for use across multiple solid tumors—including renal and colorectal cancers—our therapy is supported by a companion plasma biomarker in development to identify patients most likely to respond, enabling truly personalized treatment.
Our lead program targets adapted, treatment-resistant tumors—tackling a critical unmet need in major solid cancers, including renal and colorectal.
With a first-in-class mechanism, strong IP protection, and a companion plasma biomarker in development, AtG offers a capital-efficient, high-value opportunity for investors and partners to back a transformative oncology asset with significant commercial upside.
